NCT01459926
Completed
Phase 2
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
Overview
- Phase
- Phase 2
- Intervention
- TD-1211
- Conditions
- Opioid Induced Constipation
- Sponsor
- Theravance Biopharma
- Enrollment
- 217
- Locations
- 1
- Primary Endpoint
- Change from baseline in the weekly average CSBMs over Weeks 2 to 5 of treatment
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects with Opioid-Induced Constipation
Investigators
Eligibility Criteria
Inclusion Criteria
- •History of constipation with onset after initiation of opioid therapy
- •Self-reported OIC of approximately 3 spontaneous bowel movements (SBMs) per week or less for each week over at least the previous two week period
- •Have used chronic opioids with a total daily dose ≥30 mg of morphine equivalent units (MEU, Appendix 7) for the 12 weeks preceding the Screening Visit. Subjects should have used a stable daily regimen of opioids for at least the 2 weeks preceding the Screening Visit
- •Willing to stop all laxatives and other bowel regimens with the exception of bisacodyl/enema treatment allowed per protocol throughout the OIC confirmation, treatment, and follow-up periods
Exclusion Criteria
- •Have participated in a clinical trial of an investigational drug or medical device within 30 days prior to Screening
- •Have any condition that may affect drug absorption, (e.g., previous GI surgery)
- •Any other condition which, in the opinion of the investigator, could confound or interfere with evaluation of safety or tolerability of the investigational drug, or prevent compliance with the study protocol
Arms & Interventions
Dose 2
Intervention: TD-1211
Dose 3
Intervention: TD-1211
Dose 1
Intervention: TD-1211
Placebo
Intervention: Placebo
Outcomes
Primary Outcomes
Change from baseline in the weekly average CSBMs over Weeks 2 to 5 of treatment
Time Frame: Between weeks 2 and 5
Secondary Outcomes
- Change from baseline in the weekly SBM frequency in the last week of treatment(baseline and 5 weeks)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in KoreanAcute MigraineNCT04218162IlDong Pharmaceutical Co Ltd294
Completed
Phase 3
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian AncestryAsthmaNCT01498653GlaxoSmithKline313
Terminated
Phase 2
A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT03517566Novartis Pharmaceuticals293
Not Yet Recruiting
Phase 2
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving ChemotherapyMetastatic Breast CancerNCT06151249Chung Shan Medical University32
Terminated
Phase 2
Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease FatigueMetastatic Breast CancerFatigueNCT02645175Meriyana Bio Inc.3